Penumbra, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Adam Elsesser
- Full Time Employees
- 4,700
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- One Penumbra Place Alameda CA United States 94502
- IPO Date
- Sep 18, 2015
- CIK
- 0001321732
- Website
- penumbrainc.com
- Similar Companies
- Business
- Penumbra, Inc. (NYSE: PEN) is a global healthcare company that designs, develops, manufactures, and markets innovative medical devices for neurovascular and peripheral vascular interventions; thrombectomy systems including the Penumbra System, CAT RX aspiration catheters, RED catheters, Lightning Flash, Lightning Bolt 7, and computer-assisted vacuum thrombectomy (CAVT) technologies such as Thunderbolt; embolization products like the Ruby XL System, Swift Coil System, and SwiftSET Neuro Embolization Coil; neurosurgical tools including the Artemis Neuro Evacuation Device; and virtual reality-based rehabilitation offerings through the REAL System. Founded in 2004 and headquartered in Alameda, California, the company operates in over 100 markets worldwide through direct sales organizations and distributors, serving healthcare providers, hospitals, and clinics with solutions for ischemic stroke, hemorrhagic stroke, pulmonary embolism, peripheral artery disease, venous thromboembolism, aneurysms, and related vascular conditions. In recent developments, Penumbra announced a $200 million share repurchase authorization in August 2024, including a $100 million accelerated share repurchase agreement with JPMorgan Chase Bank; launched the SwiftSET Neuro Embolization Coil and expanded its CAVT portfolio with forthcoming Thunderbolt and Ruby XL devices highlighted at TCT 2025; reported third-quarter 2025 revenue of $354.7 million, up 17.8% year-over-year; and presented new clinical data from the STORM-PE trial and STRIKE-PE analyses demonstrating CAVT's efficacy in improving outcomes for pulmonary embolism patients.
Company News
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
IART vs. PEN: Which Stock Is the Better Value Option?
Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?
IART or PEN: Which Is the Better Value Stock Right Now?
Reasons to Retain Penumbra Stock in Your Portfolio for Now
TFX vs. PEN: Which Stock Is the Better Value Option?
Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN
TFX or PEN: Which Is the Better Value Stock Right Now?
TFX vs. PEN: Which Stock Is the Better Value Option?
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN
California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp
3 Medical Device Stocks Giving Investors a Different Healthcare Play
IQV vs. PEN: Which Stock Is the Better Value Option?
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke